Zanubrutinib and lenalidomide to prevent DLBCL return
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether taking two pills—zanubrutinib and lenalidomide—after finishing chemotherapy can help keep your DLBCL from coming back. It’s for patients who are already in complete remission after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have been diagnosed with diffuse large B-cell lymphoma (DLBCL).
- You must have finished your planned chemotherapy and be in complete remission (no signs of lymphoma left).
- Your blood counts (white blood cells, platelets, and hemoglobin) must be at safe levels, as checked by your doctor.
- You should not have an active infection or unstable health problems (like severe heart, liver, or kidney disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (Pola-ZR2P) for people with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) who have not had chemotherapy yet. It aims to see if this treatment is safe and effective.
This study tests a pill called zanubrutinib as a follow-up treatment for people with DLBCL (a type of blood cancer) who are too frail or older to receive more intensive chemotherapy but whose cancer has already shrunk after initial treatment. The goal is to see if this maintenance therapy helps keep the cancer in remission and improves outcomes.
This trial tests a new combination: zanubrutinib (a targeted pill) plus standard chemotherapy (R-CHOP) for people newly diagnosed with DLBCL whose cancer cells have high p53 protein levels. The goal is to see if adding this drug helps shrink tumors better than chemotherapy alone.
This trial tests a targeted drug called zanubrutinib combined with standard chemotherapy (R-CHOP) for people with DLBCL who have specific genetic changes in their tumor. The goal is to see if adding this drug can improve outcomes.
This Phase 2 trial studies targeted drugs combined with R-ICE chemotherapy in people with diffuse large B-cell lymphoma (DLBCL) that has come back or hasn’t responded. It may help shrink the lymphoma after prior treatment.
This trial tests different combinations of targeted drugs and chemotherapy for people newly diagnosed with a type of lymphoma called DLBCL. It aims to find which combination is more effective and safer.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.